Carragee, E. J. Hurwitz, E. L. Weiner, B. K., “A Critical Review of Recombinant Human Bone Morphogenetic Protein-2 Trials in Spinal Surgery: Emerging Safety Concerns and Lessons Learned,” Spine Journal 11, no. 6 (2011): 471–491, at 471 and 475.CrossRefGoogle Scholar

Carragee, E. J. Ghanayem, A. J. Weiner, B. K. Rothman, D. J. Bono, C. M., “A Challenge to Integrity in Spine Publications: Years of Living Dangerously with the Promotion of Bone Growth Factors,” Spine Journal 11, no. 6 (2011): 463–468, at 464.CrossRefGoogle Scholar

Fauber, J., “Journal Editor's Bonanza Research Articles Favorable to Provider of Royalties Appear with Regularity,” Milwaukee Journal Sentinel, December 29, 2009, at 1A.Google Scholar

Saul, S., “Doctor Is Accused of Giving Drug's Maker Advance Look at Critical Article,” New York Times, January 31, 2008, at C10.Google Scholar

Jones, A., “Psychiatrist to Leave Medical Journal Post; Emory Scientist's Article Criticized,” Atlanta Journal-Constitution, August 29, 2006, at 1B. Carey, B., “Correcting the Errors of Disclosure,” New York Times, July 25, 2006, at F5. Nemeroff, C. B. Mayberg, H. S. Krahl, S. E. et al. , “VNS Therapy in Treatment-Resistant Depression: Clinical Evidence and Putative Neurobiological Mechanisms,” Neuropsychopharmacology 31, no. 7 (2006): 1345–1355.Google Scholar

Becker, A. Dorter, F. Eckhardt, K. et al. , “The Association between a Journal's Source of Revenue and the Drug Recommendations Made in the Articles It Publishes,” Canadian Medical Association Journal 183, no. 5 (2011): 544–548. Kesselheim, A. S., “Covert Pharmaceutical Promotion in Free Medical Journals,” Canadian Medical Association Journal 183, no. 5 (2011): 534–535.CrossRefGoogle Scholar

For discussion of the Conflicts of interest of editors and journals, see, for example, Haivas, I. Schroter, S. Waechter, F. Smith, R., “Editors' Declaration of Their Own Conflicts of Interest,” Canadian Medical Association Journal 171, no. 5 (2004): 475–476. Sepkowitz, K., “Under the Influence? Drug Companies, Medical Journals, and Money,” Slate, September 10, 2007, available at <http://www.slate.com/articles/health_and_science/medical_examiner/2007/09/under_the_influence.html>(last visited July 25, 2012). Lexchin, J. Light, D. W., “Commercial Influence and the Content of Medical Journals,” BMJ 352, no. 7555 (2006): 1444–1447. Lundh, A. Barbateskovic, M. Hrobjartsson, A. Gotzche, P. C., “Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study,” PLoS Medicine 7, no. 10 (2011): e1000354. Marcovitch, H., “Editors, Publishers, Impact Factors, and Reprint Income,” PLoS Medicine 7, no. 10 (2010); e1000355. Joelving, F., “Financial Transparency Skin-deep at Medical Journals,” Reuters Health, June 8, 2011, available at <http://www.reuters.com/article/2011/06/08/us-medicaljournals-conflicts-idUSTRE75761520110608>(last visited July 25, 2012). “Editors Not Immune,” Reuters Health, June 8, 2011, <http://www.reuters.com/article/2011/06/08/us-financial-transparency-sidebar-idUSTRE7574YR20110608>(last visited July 25, 2012). Lanier, W. L., “Bidirectional Conflicts of Interest Involving Industry and Medical Journals: Who Will Champion Integrity?” Mayo Clinic Proceedings 84, no. 9 (2009): 771–775. Smith, J., “Should Journals Sell Reprints? Yes,” BMJ 343 (2011): d6428. Jefferson, T., “Should Journals Sell Reprints? No,” BMJ 343 (2011): D6448. Wong, V. S. Callaham, M. L., “Medical Journal Editors Lacked Familiarity with Scientific Publication Issues Despite Training and Regular Exposure,” Journal of Clinical Epidemiology 65, no. 3 (2012): 247–252.CrossRefGoogle Scholar

Relman, A. S., “Dealing with Conflicts of Interest,” New England Journal of Medicine 310, no. 18 (1984): 1182–1183. Kassirer, J. P. Angell, M., “Financial Conflicts of Interest in Biomedical Research,” New England Journal of Medicine 329, no. 8 (1993): 570–571.CrossRefGoogle Scholar

Relman, A. S., “New ‘Information for Authors’ – and Readers,” New England Journal of Medicine 323, no. 1 (1990): 56. Angell, M. Kassirer, J. P., “Editorials and Conflicts of Interest,” New England Journal of Medicine 335, no. 14 (1996): 1055–1056.CrossRefGoogle Scholar

Drazen, J. M. Curfman, G. D., “Financial Associations of Authors,” New England Journal of Medicine 346, no. 24 (2002): 1901–1902.CrossRefGoogle Scholar

Lo, B. Field, M. J., eds., Conflict of Interest in Medical Research, Education, and Practice (Washington, D.C.: National Academies Press, 2009): At 46–47. Steinbrook, R., “Controlling Conflict of Interest – Proposals from the Institute of Medicine,” New England Journal of Medicine 360, no. 21 (2009): 2160–2163. Thompson, D. F., “Understanding Financial Conflicts of Interest,” New England Journal of Medicine 329, no. 8 (1993): 573–576.Google Scholar

See Lo, supra note 11, at 47.Google Scholar

Loewenstein, G. Sah, S. Cain, D. M., “The Unintended Consequences of Conflict of Interest Disclosure,” JAMA 307, no. 7 (2012): 669–670. Cain, D. M. Loewenstein, G. Moore, D. A., “The Dirt on Coming Clean: Perverse Effects of Disclosing Conflicts of Interest,” Journal of Legal Studies 34, no. 1 (2005): 1–25. Rosenthal, E., “I Disclose…Nothing,” New York Times, January 22, 2012: SR1. Cosgrove, L. Krimsky, S., “A Comparison of DSM-IV and DSM-5 Panel Members' Financial Associations with Industry: A Pernicious Problem Persists,” PLoS Medicine 9, no. 3 (2012): e1001190; The PLoS Medicine Editors, “Does Conflict of Interest Disclosure Worsen Bias?” PLoS Medicine 9, no.4 (2012): e1001210.CrossRefGoogle Scholar

Steinbrook, R. Kassirer, J. P., “Data Availability for Industry Sponsored Trials: What Should Medical Journals Require?” BMJ 341 (2010): C5391.CrossRefGoogle Scholar

See Kesselheim, supra note 6.Google Scholar

See <www.icmje.org>(last visited August 16, 2012).(last+visited+August+16,+2012).>Google Scholar

International Committee of Medical Journal Editors, “Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication,” available at <http://www.icmje.org>(last visited August 21, 2012).(last+visited+August+21,+2012).>Google Scholar

For example, see World Association of Medical Editors, “Conflict of Interest in Peer-Reviewed Medical Journals,” available at <http://www.wame.org/resources/publication-ethics-policies-for-medical-journals>(last visited July 25, 2012); Scott-Lichter, D. and the Editorial Policy Committee, Council of Science Editors, “CSE's White Paper on Promoting Integrity in Scientific Journal Publications,” Reston, VA, available at <http://www.councilscienceeditors.org/i4a/pages/index.cfm?pageid=3313>(last visited July 25, 2012); Committee on Publication Ethics, “Code of Conduct and Best Practice Guidelines for Journal Editors,” available at <http://publicationethics.org/resources/guidelines>(last visited July 25, 2012); Committee on Publication Ethics, “Code of Conduct for Journal Publishers,” available at <http://publicationethics.org/resources/guidelines>(last visited August 21, 2012). Goozner, M. Caplan, A. Moreno, J. Kramer, B. S. Babor, T. F. Husser, W. C., “A Common Standard for Conflict of Interest Disclosure in Addiction Journals,” Addiction 104, no 11 (2009): 1779–1784.Google Scholar

See International Committee of Medical Journal Editors, supra note 17.Google Scholar

See <http://www.icmje.org/coi_disclosure.pdf>(last visited August 16, 2012).(last+visited+August+16,+2012).>Google Scholar

International Committee of Medical Journal Editors, “ICMJE Form for Disclosure of Potential Conflicts of Interest,” available, at <http://www.icmje.org>(last visited July 24, 2012); Drazen, J. M. de Leeuw, P. W. Laine, C. et al. , “Toward More Uniform Conflict Disclosures: The Updates ICMJE Conflict of Interest Reporting Form,” available at <http://www.icmje.org>(last visited July 26, 2012). Drazen, J. M. Van Der Weyden, M. B. Sahni, P. et al. , “Uniform Format for Disclosure of Competing Interests in ICMJE Journals,” available at <http://www.icmje.org/update.html>(last visited July 24, 2012).(last+visited+July+24,+2012);+Drazen,+J.+M.+de+Leeuw,+P.+W.+Laine,+C.,+“Toward+More+Uniform+Conflict+Disclosures:+The+Updates+ICMJE+Conflict+of+Interest+Reporting+Form,”+available+at+(last+visited+July+26,+2012).+Drazen,+J.+M.+Van+Der+Weyden,+M.+B.+Sahni,+P.,+“Uniform+Format+for+Disclosure+of+Competing+Interests+in+ICMJE+Journals,”+available+at+(last+visited+July+24,+2012).>Google Scholar

Blum, J. A. Freeman, K. Dart, R. C. Cooper, R. J., “Requirements and Definitions in Conflict of Interest Policies of Medical Journals,” JAMA 302, no. 20 (2009): 2230–2234. Kesselheim, A. S. Lee, J. L. Avorn, J. Servi, A. Shrank, W. H. Choudhry, N. K., “Conflict of Interest in Oncology Publications: A Survey of Disclosure Policies and Statements,” Cancer 118, no. 1 (2012): 188–195. Okike, K. Kocher, M. S. Wei, E.X. Mehlman, C. T. Bhandari, M., “Accuracy of Conflict-of-Interest Disclosures Reported by Physicians,” New England Journal of Medicine 361, no. 15 (2009): 1466–1474. Chimonas, S. Frosch, Z. Rothman, D. J., “From Disclosure to Transparency: The Use of Company Payment Data,” Archives of Internal Medicine 171, no. 1 (2011): 81–86. Kesselheim, A. S. Wang, B. Studdert, D. M. Avorn, J., “Conflict of Interest Reporting by Authors Involved in Promotion of Of-Label Drug Use: An Analysis of Journal Disclosures,” PLoS Medicine 9, no. 8 (2012): e1001280. Weinfurt, K. P. Seils, D. M. Tzeng, J.P. Lin, L. Schulman, K. A. Califf, R. M., “Consistency of Financial Interest Disclosures in the Biomedical Literature: The Case of Coronary Stents,” PLoS ONE 3, no. 5 (2008): e2128. Hirsch, L. J., “Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications: The Tort Bar and Editorial Oversight of Medical Journals,” Mayo Clinic Proceedings 84, no. 9 (2009): 811–821. Letters to the Editor, “Conflict of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications,” Mayo Clinic Proceedings 85, no. 2 (2010): 196–205. Ju, B. L. Miller, C. P. Whang, P. G. Grauer, J. N., “Quantifying the Variability of Financial Disclosure Information Reported by Authors Presenting at Annual Spine Conferences,” Spine Journal 11, no. 1 (2011): 1–8. Jegede, K. Whang, P. Grauer, J. N., “Substantial Variation in the Interpretation of Financial Disclosure Policies for Orthopaedic Society Meetings,” Journal of Bone and Joint Surgery 93, no. 13 (2011): e75. Forbes, T. L., “Author Disclosure of Conflict of Interest in Vascular Surgery Journals,” Journal of Vascular Surgery 54, no. 3 (2011): 55S–58S. Slagle, E. Sinacore, J. Brubaker, L., “Conflict of Interest Disclosure in Obstetrics & Gynecology,” Obstetrics & Gynecology 118, no. 5 (2011): 1108–1110. Khurana, G. Henderson, S. Walter, G. Martin, A. “Conflict of Interest and Disclosure Policies in Psychiatry and Medicine: A Comparative Study of Peer-Reviewed Journals,” Academic Psychiatry 36, no. 1 (2012): 17–22; see Joelving, , supra note 7.CrossRefGoogle Scholar

See Blum, supra note 22.Google Scholar

See Kesselheim, Lee, , supra note 22.Google Scholar

See Okike, supra note 22.Google Scholar

See Chimonas, supra note 22.Google Scholar

See Kesselheim, Wang, , supra note 22.Google Scholar

Braunwald, E., “Differences in an Author's Conflict of Interest Disclosures,” JAMA 307, no. 6 (2012): 561.CrossRefGoogle Scholar

Bauchner, H. Fontanarosa, P. B., “Update on JAMA's Policies on Conflicts of Interest, Trial Registration, Embargo and Data Timeliness, Access, and Analysis,” JAMA 308, no. 2 (2012): 186–188.Google Scholar

Steinbrook, R. Ross, J. S., “‘Transparency Reports’ on Industry Payments to Physicians and Teaching Hospitals,” JAMA 307, no. 10 (2012): 1029–1030.CrossRefGoogle Scholar

See <projects.propublica.org/docdollars> (last visited August 16, 2012).+(last+visited+August+16,+2012).>Google Scholar

See <www.pharmashine.com>(last visited August 16, 2012).(last+visited+August+16,+2012).>Google Scholar

See Bauchner, , supra note 29.Google Scholar

Carragee, E. J. Hurwitz, E. L. Weiner, B. K. Bono, C. M. Rothman, D. J., “Future Directions for The Spine Journal: Managing and Reporting Conflict of Interest Issues,” Spine Journal 11, no. 8 (2011): 695–697. Rosen, C. D., “It's Not about the Money,” Spine Journal 11, no. 8 (2011): 700–702.CrossRefGoogle Scholar

Smith, R., “Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies,” PLoS Medicine 2, no. 5 (2005): e138.CrossRefGoogle Scholar

Angell, M., “Industry-Sponsored Clinical Research: A Broken System,” JAMA 300, no. 9 (2008): 1069–1071.CrossRefGoogle Scholar

See International Committee of Medical Journal Editors, supra note 17.Google Scholar

See Steinbrook, supra note 14.Google Scholar

See Drazen, supra note 10.Google Scholar

Kassirer, J. P., “What the New England Journal of Medicine Did,” BMJ 343 (2011): D5665. Godlee, F., “Turning the Tide on Conflicts of Interest,” BMJ 343 (2011): D5147. Siwek, J., “American Family Physician has Prohibited Using Editorialists with Industry Ties For Over 20 Years,” BMJ 343 (2011): D5651.CrossRefGoogle Scholar

BMJ, “Editorial Staff,” available at <http://www.bmj.com/about-bmj/editorial-staf>(last visited July 25, 2012); PloS Medicine, “Competing Interests of the PLoS Medicine Editors,” available at <http://www.plosmedicine.org/static/editorsInterests.action>(last visited July 25, 2012).(last+visited+July+25,+2012);+PloS+Medicine,+“Competing+Interests+of+the+PLoS+Medicine+Editors,”+available+at+(last+visited+July+25,+2012).>Google Scholar

See Lundh, , supra note 7.Google Scholar

Handel, A. E. Patel, S. V. Pakpoor, J. Ebers, G. C. Goldacre, B. Ramagopalan, S. V., “High Reprint Orders in Medical Journals and Pharmaceutical Industry Funding: Case-Control Study,” BMJ 344 (2012): e4212.CrossRefGoogle Scholar

The PLoS Medicine Editors, “Increased Responsibility and Transparency in an Era of Increased Visibility,” PLoS Medicine 7, no. 10 (2010): e1000364; BMJ Group, “Revenue Sources,” available at <http://group.bmj.com/group/about/revenue-sources>(last visited July 24, 2012); BMJ Group, “BMJ Group Advertising and Sponsorship Policy,” available at <http://group.bmj.com/group/advertising/policy>(last visited July 26, 2012).(last+visited+July+24,+2012);+BMJ+Group,+“BMJ+Group+Advertising+and+Sponsorship+Policy,”+available+at+(last+visited+July+26,+2012).>Google Scholar

See Carragee, supra note 34.Google Scholar

American Medical Student Association, “AMSA PharmFree Scorecard, 2011–2012, Executive Summary, Updated March 7, 2012,” available at <http://www.amsascorecard.org/executive-summary>(last visited July 26, 2012).(last+visited+July+26,+2012).>Google Scholar